Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor
Por:
Jimeno, J, Varona, JF, Lopez-Martin, JA, Izquierdo-Useros, N, Molina, EM, Guisado-Vasco, P, Sachse, M, Risco, C, Losada, A, Fudio, S, Luepke, E, Nieto, A, Gomez, J, Aviles, P, Cuevas, C, Bouhaddou, M, Sola, I, Krogan, NJ, Enjuanes, L, Fernandez-Sousa, JM, GarcIa-Sastre, A and White, K
Publicada:
1 dic 2025
Ahead of Print:
1 nov 2025
Resumen:
Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis.
Filiaciones:
Jimeno, J:
PharmaMar R&D, Madrid, Spain
Novita Pharmaceut, New York, NY 10065 USA
Varona, JF:
Univ Camilo Jose Cela, Hosp Univ HM Monteprincipe, HM Hosp, Dept Med Interna, Madrid, Spain
Univ Camilo Jose Cela, Inst Invest Sanitaria HM Hosp, Fac HM Ciencias Salud CUHMED, Madrid, Spain
Lopez-Martin, JA:
PharmaMar R&D, Madrid, Spain
Atrys Hlth, Madrid, Spain
:
IrsiCaixa, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Infecciosas, CIBERINFEC, Madrid, Spain
Inst Germans Trias & Pujol, Badalona, Spain
:
IrsiCaixa, Barcelona, Spain
Guisado-Vasco, P:
Hosp Univ Quironsalud, Dept Internal Med, Madrid, Spain
European Univ, Madrid, Spain
Sachse, M:
Univ Autonoma, Ctr Nacl Biotecnol Severo Ochoa, Madrid, Spain
Risco, C:
Univ Autonoma, Ctr Nacl Biotecnol Severo Ochoa, Madrid, Spain
Losada, A:
PharmaMar R&D, Madrid, Spain
Fudio, S:
PharmaMar R&D, Madrid, Spain
Luepke, E:
PharmaMar R&D, Madrid, Spain
Nieto, A:
PharmaMar R&D, Madrid, Spain
Gomez, J:
PharmaMar R&D, Madrid, Spain
Aviles, P:
PharmaMar R&D, Madrid, Spain
Cuevas, C:
PharmaMar R&D, Madrid, Spain
Bouhaddou, M:
Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA
J David Gladstone Inst, Quantitat Biosci Inst, San Francisco, CA USA
Krogan, NJ:
J David Gladstone Inst, Quantitat Biosci Inst, San Francisco, CA USA
Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA USA
J David Gladstone Inst, Gladstone Inst Data Sci & Biotechnol, San Francisco, CA 94158 USA
Quantitat Biosci Inst QBI, COVID 19 Res Grp QCRG, San Francisco, CA 94158 USA
Fernandez-Sousa, JM:
PharmaMar R&D, Madrid, Spain
GarcIa-Sastre, A:
Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA
Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY USA
Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY USA
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
ISMMS, Dept Pathol Mol & Cell Based Med, New York, NY USA
ISMMS, Icahn Genom Inst, New York, NY USA
White, K:
Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA
Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY USA
|